Article
Surgery
Luca Saragoni, Leonardo Solaini, Daniele Marrelli, Maria Raffaella Ambrosio, Maria Bencivenga, Anna Tomezzoli, Carlo Milandri, Valentina Terrinazzi, Gian Luca Baiocchi, Carla Baronchelli, Flavia Foca, Giorgio Ercolani, Paolo Morgagni
Summary: This study validates a nodal regression system for gastric cancer and demonstrates its significant correlation with prognosis, as well as its impact on clinico-pathological characteristics and prognosis.
INTERNATIONAL JOURNAL OF SURGERY
(2021)
Article
Multidisciplinary Sciences
Yaobin Lin, Lei Wang, Lingdong Shao, Xueqing Zhang, Huaqin Lin, Youjia Wang, Junxin Wu
Summary: A study on the clinical efficacy of adjuvant external beam radiotherapy for patients with pathologic stage T4b sigmoid colon cancer found that patients who received adjuvant EBRT had a significantly longer median overall survival compared to those who did not receive radiation therapy. Age, serum carcinoembryonic antigen (CEA) level, perineural invasion, lymph node dissection (LND) number, and adjuvant EBRT were identified as independent factors associated with overall survival. A risk-stratification model was developed to predict the outcomes of high-risk patients based on specific factors.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Zhonglin Hao, Saurabh Parasramka, Quan Chen, Aasems Jacob, Bin Huang, Timothy Mullett, Al B. Benson
Summary: For resectable colon cancer with synchronous liver or lung metastasis, neoadjuvant chemotherapy before surgical resection of all lesions, especially in non-academic settings, has shown an overall survival advantage over adjuvant chemotherapy after surgery.
Article
Oncology
Bogdan Badic, Anne-Marie Bouvier, Veronique Bouvier, Marie Morvan, Valerie Jooste, Arnaud Alves, Jean-Baptiste Nousbaum, Noemi Reboux
Summary: In elderly patients with metastatic colon cancer, low comorbidity burden, curative surgery, and chemotherapy have a significant advantage in terms of overall survival. The location of metastasis, but not of the primary tumor, impacts survival outcomes.
Article
Surgery
Hidetaka Kawamura, Yusuke Ogawa, Hajime Yamazaki, Michitaka Honda, Koji Kono, Shinichi Konno, Shunichi Fukuhara, Yosuke Yamamoto
Summary: The study analyzed data from nine designated cancer hospitals in Fukushima Prefecture, Japan, and found that undergoing primary tumor resection before systemic chemotherapy was associated with improved survival in patients with metastatic colorectal cancer (mCRC).
WORLD JOURNAL OF SURGERY
(2021)
Article
Oncology
Zhen Yang, Guangjun Shi, Ping Zhang
Summary: This study aimed to develop nomograms to predict survival outcomes in patients with pancreatic adenosquamous carcinoma (PASC). Data from the SEER database were analyzed, and prediction models were constructed based on the identified predictors. The nomograms provide a useful tool for calculating individualized survival estimates and assisting in risk stratification and clinical decision-making.
FRONTIERS IN ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Bogdan Badic, Maude Oguer, Melanie Cariou, Tiphaine Kermarrec, Servane Bouzeloc, Jean-Baptiste Nousbaum, Michel Robaszkiewicz, Lucille Queneherve
Summary: Age, comorbidities, tumor histology, and adjuvant chemotherapy were identified as independent predictors of prognosis in elderly patients with stage III colon cancer. These findings could help identify elderly patients with poor prognosis and assist in the design of tailored randomized clinical trials in the future.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2021)
Article
Gastroenterology & Hepatology
Hillary L. Simon, Thais Reif de Paula, Zachary A. Spigel, Deborah S. Keller
Summary: In the USA, adjuvant chemotherapy is underutilized in N1c colon cancer despite significantly improved overall survival. Factors such as age, gender, comorbidities, and treatment center type may influence the use of adjuvant chemotherapy.
COLORECTAL DISEASE
(2021)
Article
Medicine, General & Internal
Jeanne Tie, Joshua D. Cohen, Kamel Lahouel, Serigne N. Lo, Yuxuan Wang, Suzanne Kosmider, Rachel Wong, Jeremy Shapiro, Margaret Lee, Sam Harris, Adnan Khattak, Matthew Burge, Marion Harris, James Lynam, Louise Nott, Fiona Day, Theresa Hayes, Sue-Anne McLachlan, Belinda Lee, Janine Ptak, Natalie Silliman, Lisa Dobbyn, Maria Popoli, Ralph Hruban, Anne Marie Lennon, Nicholas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Cristian Tomasetti, Peter Gibbs
Summary: This study found that using ctDNA results to guide treatment decisions for stage II colon cancer reduced the use of adjuvant chemotherapy without compromising recurrence-free survival.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Smita Sihag, Samuel C. Nussenzweig, Henry S. Walch, Meier Hsu, Kay See Tan, Sergio De La Torre, Yelena Y. Janjigian, Steven B. Maron, Geoffrey Y. Ku, Laura H. Tang, Pari M. Shah, Abraham Wu, David R. Jones, David B. Solit, Nikolaus Schultz, Karuna Ganesh, Michael F. Berger, Daniela Molena
Summary: MDM2 amplification and TP53 status are associated with response to therapy in patients with esophageal adenocarcinoma. Worsening TP53 dysfunction is directly correlated with worse treatment outcomes.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Lauren M. Theiss, Adam T. Lucy, Shelby L. Bergstresser, Daniel Chu, Gregory D. Kennedy, Robert Hollis, Kelly M. Kenzik
Summary: Patient, societal, and hospital factors impact whether patients receive guideline-adherent colon cancer care. Interventions are needed to improve access to timely and guideline-adherent cancer care as a possible mechanism to combat surgical disparities.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Antoni Llueca, Maria Teresa Climent, Javier Escrig, Paula Carrasco, Anna Serra, L. Gomez-Quiles, R. Jativa, G. Cebrian, V Bosso, A. Villarin, K. Maiocchi, K. Delgado-Barriga, M. Rodrigo-Aliaga, N. Ruiz, C. Herrero, A. Frances, I Beato, C. Ferrer, J. P. Aracil, E. Boldo, A. Boldo, R. Adell
Summary: This study validated the predictive value of three models for predicting suboptimal cytoreductive surgery in advanced ovarian cancer, showing better reliability in predicting complete cytoreductive surgery.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Leila M. Boustany, Sherry L. LaPorte, Laurie Wong, Clayton White, Veena Vinod, Joel Shen, Wendy Yu, David Koditek, Michael B. Winter, Stephen J. Moore, Li Mei, Linnea Diep, Yuanhui Huang, Shouchun Liu, Olga Vasiljeva, Jim West, Jennifer Richardson, Bryan Irving, Marcia Belvin, W. Michael Kavanaugh
Summary: T cell-engaging bispecific antibodies (TCB) are highly potent therapeutics that can recruit and activate cytotoxic T cells to stimulate an antitumor immune response. However, the development of TCBs against solid tumors has been limited by significant on-target toxicity to normal tissues. Probody TCB, targeting EGFR and CD3, has been developed as a novel approach to reduce toxicity to normal tissues and enhance efficacy against solid tumors.
Article
Oncology
Leila M. Boustany, Sherry L. LaPorte, Laurie Wong, Clayton White, Veena Vinod, Joel Shen, Wendy Yu, David Koditek, Michael B. Winter, Stephen J. Moore, Li Mei, Linnea Diep, Yuanhui Huang, Shouchun Liu, Olga Vasiljeva, Jim West, Jennifer Richardson, Bryan Irving, Marcia Belvin, W. Michael Kavanaugh
Summary: This article describes the development of Probody TCB, a novel therapeutic drug that targets EGFR and CD3 and selectively releases its activity in the tumor microenvironment, thereby reducing toxicity to normal tissues. The preclinical studies showed that the drug effectively inhibited tumor growth in vitro and in vivo, while exhibiting lower toxicity in animal models compared to unmasked TCB.
Article
Oncology
Dion Morton, Matthew Seymour, Laura Magill, Kelly Handley, James Glasbey, Bengt Glimelius, Andy Palmer, Jenny Seligmann, Soren Laurberg, Keigo Murakami, Nick West, Philip Quirke, Richard Gray, FOxTROT Collaborative Grp
Summary: Neoadjuvant chemotherapy shows potential benefits for locally advanced colon cancer compared to postoperative chemotherapy. In this study, patients with radiologically staged T3-4, N0-2, M0 colon cancer were randomly assigned to receive 6 weeks of preoperative oxaliplatin-fluoropyrimidine chemotherapy followed by either 18 or 24 weeks postoperatively. Results indicate that neoadjuvant chemotherapy results in marked downstaging of tumors and lower rates of incomplete resections and disease recurrence within 2 years.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Pathology
Monika Vyas, Jaclyn F. Hechtman, Yanming Zhang, Ryma Benayed, Aslihan Yavas, Gokce Askan, Jinru Shia, David S. Klimstra, Olca Basturk
Article
Cell Biology
Jinru Shia
Summary: Microsatellite instability (MSI) is recognized as a diverse molecular phenotype in human neoplasms, with variations in genotype and phenotype within and across tumor types. Advances in understanding this diversity have been made, but its potential impact on the effective use of current MSI detection tools is significant.
Article
Oncology
Martin R. Weiser, Meier Hsu, Philip S. Bauer, William C. Chapman, Ivan A. Gonzalez, Deyali Chatterjee, Deepak Lingam, Matthew G. Mutch, Ajaratu Keshinro, Jinru Shia, Efsevia Vakiani, Tsuyoshi Konishi, Yoshifumi Shimada, Zsofia Stadler, Neil H. Segal, Andrea Cercek, Leonard Saltz, Rona Yaeger, Anna Varghese, Maria Widmar, Iris H. Wei, Emmanouil P. Pappou, J. Joshua Smith, Garrett Nash, Philip Paty, Julio Garcia-Aguilar, Mithat Gonen
Summary: Clinical calculators and nomograms are recommended by the AJCC for providing individualized and accurate estimates of patient outcome. A third-generation clinical calculator was developed to predict cancer recurrence following resection of stage I-III colon cancer, demonstrating improved discrimination and predictive accuracy by incorporating new variables such as microsatellite genomic phenotype and tumor-infiltrating lymphocytes.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Letter
Pathology
Jaclyn F. Hechtman, Robert Soslow, Jinru Shia
Article
Pathology
Monika Vyas, Erika Hissong, Raul S. Gonzalez, Jinru Shia, Jose Jessurun
Summary: This study aimed to investigate the most common tumors that metastasize to the stomach and the morphologic features that can provide clues for investigation of metastasis and predicting the primary sites. The results showed that gastric neoplasms with a diffuse/solid growth pattern should be considered for differential diagnosis of metastatic neoplasms. Glandular neoplasms are difficult to differentiate from gastric primaries except for Mullerian neoplasms, which frequently show a papillary/micropapillary architecture.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
(2022)
Article
Oncology
Lik Hang Lee, Lindy Davis, Lourdes Ylagan, Angela R. Omilian, Kristopher Attwood, Canan Firat, Jinru Shia, Philip B. Paty, William G. Cance
Summary: High expression of focal adhesion kinase (FAK) in colorectal cancer is associated with increased recurrence rate and reduced survival in stage I patients. FAK may serve as an important biomarker for predicting recurrence in stage I colorectal cancer, suggesting the need for more rigorous surveillance protocols for these patients.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Article
Oncology
Jin K. Kim, Chin-Tung Chen, Ajaratu Keshinro, Asama Khan, Canan Firat, Chad Vanderbilt, Neil Segal, Zsofia Stadler, Jinru Shia, Vinod P. Balachandran, Martin R. Weiser
Summary: T cells in colon tumors with deficient DNA mismatch repair (dMMR) are more clonal and have a less diverse repertoire compared to tumors with proficient mismatch repair (pMMR). This suggests that T cells clonally expand in response to MMR deficiency-induced tumor neoantigens in dMMR tumors.
Review
Pathology
Chiyun Wang, Liying Zhang, Efsevia Vakiani, Jinru Shia
Summary: The value of detecting tumor DNA mismatch repair function is widely recognized in managing patients with solid tumors. However, the current immunohistochemistry and microsatellite instability tests have limitations. Some non-colorectal cases may lose mismatch repair function in immunohistochemistry but do not meet the current criteria for high microsatellite instability. These cases may require further genetic testing for Lynch syndrome detection.
Article
Hematology
Doris M. Ponce, Amin M. Alousi, Ryotaro Nakamura, John Slingerland, Marco Calafiore, Karamjeet S. Sandhu, Juliet N. Barker, Sean Devlin, Jinru Shia, Sergio Giralt, Miguel-Angel Perales, Gillian Moore, Samira Fatmi, Cristina Soto, Antonio Gomes, Paul Giardina, LeeAnn Marcello, Xiaoqiang Yan, Tom Tang, Kevin Dreyer, Jianmin Chen, William L. Daley, Jonathan U. Peled, Marcel R. M. van den Brink, Alan M. Hanash
Summary: This study evaluated the safety and efficacy of a novel recombinant human interleukin-22 dimer, F-652, in combination with systemic corticosteroids for treatment of newly diagnosed lower gastrointestinal acute GVHD. The results showed that 70% of patients achieved a satisfactory treatment response, demonstrating the potential effect of this combination therapy for improving GVHD-associated dysbiosis.
Article
Oncology
Naryan Rustgi, Ann Maria, Nicolas Toumbacaris, Huiyong Zhao, Katherine Kargus, Morgan Bryant, Alexandra Waksmundzki, Ilinca Aricescu, Robert A. Lefkowitz, Bob T. Li, Joanne Chou, Marinela Capanu, Elisa de Stanchina, Sandra Misale, Jinru Shia, Rona Yaeger
Summary: This study aimed to explore the efficacy of combination therapy with RAF and MEK inhibitors for non-V600 BRAF-mutant tumors. The results showed that RAF inhibitors modestly inhibited signaling and growth in preclinical models of activated non-V600 BRAF mutations and allowed for a higher dose of MEK/ERK inhibitors. However, in a clinical trial, the combination treatment did not sufficiently inhibit the growth of these tumors.
Article
Oncology
Christine Orr, Chiyun Wang, Canan Firat, Louise C. Connell, Margaret R. Sheehan, Efsevia Vakiani, Zsofia K. Stadler, Jinru Shia
JCO PRECISION ONCOLOGY
(2022)
Article
Oncology
Ajaratu Keshinro, Chad Vanderbilt, Jin K. Kim, Canan Firat, Chin-Tung Chen, Rona Yaeger, Karuna Ganesh, Neil H. Segal, Mithat Gonen, Jinru Shia, Zsofia Stadler, Martin R. Weiser
Summary: The study characterized the relationship between TIL, TMB, and genetic alterations in MSS, MSI, or mutant POLE/POLD1 colon cancer. Results showed significant differences in TIL and TMB levels between different phenotypes, which may help explain tumoral immunity and serve as predictors of response to immunotherapy.
JCO PRECISION ONCOLOGY
(2021)
Article
Oncology
Prachi Kothari, Talia Sauerhaft, Nancy Bouvier, M. Irene Rodriguez-Sanchez, Jinru Shia, Anita Price, Sejal Morjaria, J. Theodore Gerstle, Neerav N. Shukla, Michael V. Ortiz
JCO PRECISION ONCOLOGY
(2021)
Article
Oncology
Erin E. Salo-Mullen, Anna Maio, Semanti Mukherjee, Chaitanya Bandlamudi, Jinru Shia, Yelena Kemel, Karen A. Cadoo, Ying Liu, Maria Carlo, Megha Ranganathan, Sarah Kane, Preethi Srinivasan, Shweta S. Chavan, Mark T. A. Donoghue, Caitlin Bourque, Margaret Sheehan, Prince Rainier Tejada, Zalak Patel, Angela G. Arnold, Jennifer A. Kennedy, Kimberly Amoroso, Kelsey Breen, Amanda Catchings, Rosalba Sacca, Vanessa Marcell, Arnold J. Markowitz, Alicia Latham, Michael Walsh, Maksym Misyura, Ozge Ceyhan-Birsoy, David B. Solit, Michael F. Berger, Mark E. Robson, Barry S. Taylor, Kenneth Offit, Diana Mandelker, Zsofia K. Stadler
Summary: The study analyzed NTHL1 and MSH3 gene mutations in 11,081 patients with pan-cancer, showing that these mutations were not significantly enriched in the overall patient population. However, specific tumor genetic characteristics were found in some patients, suggesting a potential contribution of monoallelic variants to tumorigenesis.
JCO PRECISION ONCOLOGY
(2021)
Article
Oncology
Rosa M. Jimenez-Rodriguez, Sujata Patil, Ajaratu Keshinro, Jinru Shia, Efsevia Vakiani, Zsofia Stadler, Neil H. Segal, Rona Yaeger, Tsuyoshi Konishi, Yoshifumi Shimada, Maria Widmar, Iris Wei, Emmanouil Pappou, J. Joshua Smith, Garrett Nash, Philip Paty, Julio Garcia-Aguilar, Martin R. Weiser